Brief: Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (Ibtrozi®) As Recommended Option
27/04/2026 13:50
April 27 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO ANNOUNCES NATIONAL COMPREHENSIVE CANCER NETWORK® ADDS TALETRECTINIB (IBTROZI®) AS RECOMMENDED OPTION TO CLINICAL PRACTICE GUIDELINES IN ONCOLOGY FOR CENTRAL NERVOUS SYSTEM CANCERS Source text: ID:nPn4vtTsGa Further company coverage: NUVB.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth